Long - Term Effect of Quinapril or Losartan or Their Combination on Diabetic Autonomic Neuropathy and Left Ventricular Function Over a Period of 4 Years. A Radionuclide Ventriculography Study.

Purpose: To investigate the effect of Quinapril (Q) or Losartan (L) or their combination on definite Diabetic Autonomic Neuropathy (DAN) and left ventricular systolic and diastolic function (LVF) over a period of 4 years.
Patients-methods: Fifty-nine patients with definite DAN [2 or more of the 4 Cardiovascular Reflex Tests (CRTs) were abnormal] were studied for 4 years. Patients were randomly allocated in 3 groups receiving A, 20 mg Q, B, 100 mg L and C, 20 mg Q +100 mg L respectively. CRTs analyzed with Mean Circular Resultant (MCR), Valsalva index, 30:15 ratio and postural hypotension. LV function was investigated with radionuclide ventriculography (RNV) at rest. Ejection fraction was used to assess LV systolic function, while peak filling rate, first third filling fraction, and atrial contribution to ventricular filling were used to investigate LV diastolic function. CRTs and RNV were performed at baseline and after 4 years.

Start Date01 Jan 2017

Sponsor / Collaborator

University Hospital AHEPA

NCT01669434

/ CompletedPhase 4IIT

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study

Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience better postoperative control of hypertension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience less acute renal failure than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.

Start Date01 Jun 2015

Sponsor / Collaborator

University of Nebraska

CTR20132627

/ Active, not recruitingNot Applicable

盐酸喹那普利片在健康男性受试者中的单次剂量、随机、开放生物等效性研究

[Translation] A single-dose, randomized, open-label bioequivalence study of quinapril hydrochloride tablets in healthy male subjects

研究健康男性受试者单次口服由武汉启瑞药业有限公司研制的盐酸喹那普利片和哈药集团制药总厂生产的盐酸喹那普利片（益恒）的相对生物利用度，评价两制剂间的生物等效性。

[Translation]

To study the relative bioavailability of a single oral dose of quinapril hydrochloride tablets developed by Wuhan Qirui Pharmaceutical Co., Ltd. and quinapril hydrochloride tablets (Yiheng) produced by Harbin Pharmaceutical Group Pharmaceutical Factory in healthy male subjects and to evaluate the bioequivalence of the two preparations.

Start Date14 Jul 2014

Sponsor / Collaborator

Wuhan Qirui Pharmaceutical Co., Ltd.

100 Clinical Results associated with Quinapril Hydrochloride

100 Translational Medicine associated with Quinapril Hydrochloride

100 Patents (Medical) associated with Quinapril Hydrochloride

1,383

Literatures (Medical) associated with Quinapril Hydrochloride

01 Jun 2025·INTERNATIONAL JOURNAL OF CARDIOLOGY

An updated review on therapeutic strategies in coronary microvascular dysfunction

Review

Author: Yong, Andy ; Khandkar, Chinmay ; Ravindran, Jayant ; Rehan, Rajan

Coronary microvascular dysfunction (CMD) is well-known cause of angina, yet treatment options remain limited. This systematic review and meta-analysis examines the current literature and provides a contemporary evaluation of treatments using a stringent definition for CMD with accurate methods of microvascular assessment in accordance with recent consensus guidelines. Methods and Results: A search strategy was conducted independently by two authors (CK and RR). Studies were required to be prospective trials in adult patients with documented CMD by IC doppler wire, thermodilution techniques, or perfusion imaging via PET/MRI. CMD was defined as either coronary flow reserve (CFR)/myocardial perfusion reserve (MPR) < 2.5, and/or index of microvascular resistance (IMR) > 25. Methodological quality of studies was assessed via the Cochrane Risk of Bias tool. The primary and secondary endpoints were change in CFR/MPR/IMR and change in Seattle Angina Questionnaire (SAQ) scores respectively. Two-sided p-values were used and considered significant if p < 0.05. A total of 11,360 records were identified, from which 14 were included in this review covering 9 different treatments. Two treatments (quinapril and ranolazine) showed significant improvement in both CFR and angina. Three ranolazine trials were pooled in meta-analysis. The standardised mean difference showed a weak positive effect (0.24) with wide intervals (-0.21 to 0.26) which was not statistically significant (p = 0.20). We subsequently reviewed all treatments as mentioned in recent European consensus statements. Conclusions: The overall quality of evidence surrounding treatments for CMD is of "low", with lack of robust data highlighting the dire need for higher quality trials in this area.

01 Apr 2025·JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY

DFT analysis for structure, vibrational assignments, and molecular properties of medicinally important isoquinoline

Author: Mir, M. Amin

2-Benzanine, also recognized as isoquinoline or benzo pyridine, acts as a weak tertiary base with diverse biol. and pharmacol. effects.These include potential activities against Parkinson's disease, antimalarial, anti-HIV, insect growth, anticancer, antibiotic, antileukemic properties, and the ability to serve as a chiral ligand scaffold.In this study, the B3LYP technique and the basis set 6-311++G(d, p) were employed for both computational and exptl. examinations of isoquinoline using d. functional theory (DFT).The findings revealed that isoquinoline possesses a dipole moment of 2.004 D and rotational constants (GHz) of 3.101, 1.22, and 0.875.Various tests, including IR, UV-visible, HNMR, and binding energies, corroborated the exptl. results.Analyzing the computed energy difference between the HOMO at -5.581 eV and the LUMO at 1.801 eV indicated the stability of isoquinoline, with an energy gap of 3.78 eV.The electron polarizability and chem. hardness values were found to be 1.89 and 0.529, resp.Drug-likeness tests suggest that isoquinoline could function as an antibiotic, given its similarity in effects to other compounds such as isoquinoline, quinolone, debrisoquine, palmatine, columbamine, and jatropine.

01 Mar 2025·JOURNAL OF FOOD COMPOSITION AND ANALYSIS

Heavy metal accumulation, yield and health risk assessment of wheat crop grown in contaminated soil amended with bioash for sustainable agriculture

Author: Kumar, Umesh ; Sharma, Rajesh Kumar ; Kumar, Indrajeet ; Singh, Prince Kumar

Prolonged use of wastewater irrigation in peri-urban agriculture has increased levels of heavy metals (HMs) in soil, raising concerns regarding both food safety and human health.To address this issue, the effectiveness of agro-waste derived bioashes (ADB), specifically rice husk ash (RHA) and sugarcane bagasse ash (SBA), was investigated as soil amendment materials to immobilize HMs in soil and reduce their accumulation in crops.The aim of the present study was to evaluate the effects of RHA and SBA on HM uptake, growth, yield, nutrient quality, and seed metabolite profiles of wheat (Triticum aestivum L. cv. HUW 234) crop grown in HM contaminated soils, along with associated health risks.Results revealed that SBA significantly and effectively reduced Cr, Ni, Cu, Zn, and Cd accumulation in wheat seeds (13.5%, 33.8%, 17.6%, 7.8%, and 10.0%, resp.), more compared to RHA (6.8%, 16.9%, 8.8%, 3.9%, and 5.0%) with maximum accumulation in roots followed by shoots and least in seeds.Health risk assessments showed that the estimated daily intake (EDI) of HMs was found highest for Zn and lowest for Cd in both the children and adults consuming wheat seeds, with hazard quotient values above a unit for all the HMs.The present study concludes that SBA could be effectively used as a superior soil amendment to reduce HM toxicity in soil-wheat system, associated human health risks and to promote sustainable agriculture in peri-urban areas.

News (Medical) associated with Quinapril Hydrochloride

14 May 2024

·www.prnewswire.com

CardioPharma Announces Issuance of Global Patent to Mitigate the World's Top Killer

WILMINGTON, N.C., May 14, 2024 /PRNewswire/ -- CardioPharma Inc. (the "Company"), a specialty pharmaceutical company focused on drug development for cardiovascular diseases, announced that on August 29, 2023, the United States Patent and Trademark Office ("USPTO") issued US Patent 11,737,988 B2 entitled "Anti-Hypertensive and Cholesterol-Lowering Fixed-Dose Combination and Method of Manufacture." Additional patents covering the subject matter of the '988 Patent have been granted in South Africa in 2022 and Australia, Armenia, Belarus, and the Russian Federation in 2024. Three further patents have been accepted in Canada, New Zealand, and Israel and will issue in the near future. In addition to the foregoing, CardioPharma is pursuing additional patents in major markets throughout the world, all of which together will bolster CardioPharma's global presence for the products covered by the patent grants. The 20-year term for all of the patents runs through April 17, 2039. CardioPharma Pipeline CardioPharma's pipeline products contain some of the world's most consumed, individually dispensed medications for the prevention and treatment of cardiovascular disease. The lead product, CardiaPill® is a unique formulation combining a cholesterol modifying agent ("statin"), an Angiotensin-converting-enzyme inhibitor (ACE Inhibitor) and anti-platelet agent. Statins moderate cholesterol levels and include products such as Lipitor®, Zocor®, Pravachol®; and Crestor®. ACE inhibitors reduce blood pressure and include products such as Altace®, Lotensin®, Capoten® and Accupril®. Pipeline products also include combinations using Angiotensin II Receptor Blockers (ARBs) as well as different statins and other anti-platelet agents. Simplicity of dosing, improved adherence and significant cost benefits for patients, providers and payors around the world are among the many compelling and well-documented benefits that make these inexpensive products so anticipated. About CardioPharma CardioPharma (), Inc. is a specialty pharmaceutical company focused on patent-protected combinatorial cardiovascular medications. CardioPharma's goal is to create drugs that make it easier and more cost-effective for doctors and their patients to reduce the morbidity and mortality of the world's number one killer – cardiovascular disease. The products are unique to the global pharmaceutical industry – highly cost-effective with proven efficacy; providing both patient and provider convenience; promoting adherence, while delivering superior clinical outcomes and economic benefits to all stakeholders. For more information, visit . Forward looking statements The information in this press release contains forward-looking statements including the prospective development, commercialization and regulatory approval in the U.S. and international markets. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors including the Company's ability to raise sufficient funds to bring new products to the global market. Contact: [email protected] SOURCE CardioPharma, Inc.

Patent Expiration

28 Feb 2024

·www.biospace.com

FDA Ramps Up Manufacturing Inspections in India: Reuters

F acade of the FDA’s office in Maryland iStock, Grandbrothers Amid the dual crises of worsening medicine quality and growing drug shortages, the FDA plans to increase inspections of Indian manufacturing facilities this year, Reuters reported Tuesday. Pictured: Facade of the FDA building in Maryland/iStock, Grandbrothers The FDA is planning to increase its inspection of drug manufacturing facilities in India this year amid growing quality and supply concerns, Reuters reported Tuesday citing an agency executive. “We are putting every effort into increasing the number of inspections,” Sarah McMullen, FDA Country Director for India, told Reuters , adding that the regulator is also “requesting more drug investigators to be stationed here.” The decision to tighten regulatory scrutiny over Indian manufacturing facilities comes as the FDA grapples with two interconnected crises: The deteriorating quality of medicines and persistent drug shortages. The FDA in its annual Report on the State of Pharmaceutical Quality, published in June 2023, documented a record number of drug recalls , which reached its highest level in five years. The report covered the agency’s fiscal year 2022, which ran from October 1, 2021 to September 30, 2022. During that timeframe, the FDA issued 912 recalls across 166 manufacturing sites, most of which were due to violations of current good manufacturing practices (CGMP). Inspections of manufacturing sites also spiked to 328 in FY2022, which was “nearly triple the amount” of such visits in the year prior. The regulator also issued a high number of import alerts and warning letters, mostly affecting facilities in China, South Korea and India. In July 2023, the House Committee on Energy and Commerce wrote to the FDA requesting detailed information regarding its inspections of foreign drug manufacturing facilities—particularly those in China and India. Committee Chair Rep. Cathy Rodgers (R-WA), along with Subcommittee Chairs Reps. Brett Guthrie (R-KY) and Morgan Griffith (R-VA), expressed their concern that the U.S. might be becoming too reliant on “foreign manufacturers with a demonstrated pattern of repeatedly violating FDA safety regulations.” The FDA is also struggling to keep up with significant shortages of hundreds of life-saving drugs. Currently, the regulator has listed over 300 medicines in short supply, the highest number since 2014. Medicines affected by the shortages include amoxicillin, quinapril, cisplatin, carboplatin and the wildly popular weight-loss therapy semaglutide. Earlier this month, the House Ways and Means Committee held a hearing to investigate these shortages, noting that most of the treatments on the FDA’s list have seen limited availability for at least two years. The growing manufacturing problems in overseas facilities has made the drug shortages worse. India-based Intas Pharmaceuticals has received a warning letter from the FDA over several quality control lapses and poor data integrity. Intas, which manufactures several generic drugs, is on the FDA’s import alert list . Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com .

28 Feb 2024

·www.biospace.com

FDA Ramps Up Manufacturing Inspections in India: Reuters

Pictured: Facade of the FDA building in Maryland/iStock, Grandbrothers The FDA is planning to increase its inspection of drug manufacturing facilities in India this year amid growing quality and supply concerns, Reuters reported Tuesday citing an agency executive. “We are putting every effort into increasing the number of inspections,” Sarah McMullen, FDA Country Director for India, told Reuters, adding that the regulator is also “requesting more drug investigators to be stationed here.” The decision to tighten regulatory scrutiny over Indian manufacturing facilities comes as the FDA grapples with two interconnected crises: The deteriorating quality of medicines and persistent drug shortages. The FDA in its annual Report on the State of Pharmaceutical Quality, published in June 2023, documented a record number of drug recalls, which reached its highest level in five years. The report covered the agency’s fiscal year 2022, which ran from October 1, 2021 to September 30, 2022. During that timeframe, the FDA issued 912 recalls across 166 manufacturing sites, most of which were due to violations of current good manufacturing practices (CGMP). Inspections of manufacturing sites also spiked to 328 in FY2022, which was “nearly triple the amount” of such visits in the year prior. The regulator also issued a high number of import alerts and warning letters, mostly affecting facilities in China, South Korea and India. In July 2023, the House Committee on Energy and Commerce wrote to the FDA requesting detailed information regarding its inspections of foreign drug manufacturing facilities—particularly those in China and India. Committee Chair Rep. Cathy Rodgers (R-WA), along with Subcommittee Chairs Reps. Brett Guthrie (R-KY) and Morgan Griffith (R-VA), expressed their concern that the U.S. might be becoming too reliant on “foreign manufacturers with a demonstrated pattern of repeatedly violating FDA safety regulations.” The FDA is also struggling to keep up with significant shortages of hundreds of life-saving drugs. Currently, the regulator has listed over 300 medicines in short supply, the highest number since 2014. Medicines affected by the shortages include amoxicillin, quinapril, cisplatin, carboplatin and the wildly popular weight-loss therapy semaglutide. Earlier this month, the House Ways and Means Committee held a hearing to investigate these shortages, noting that most of the treatments on the FDA’s list have seen limited availability for at least two years. The growing manufacturing problems in overseas facilities has made the drug shortages worse. India-based Intas Pharmaceuticals has received a warning letter from the FDA over several quality control lapses and poor data integrity. Intas, which manufactures several generic drugs, is on the FDA’s import alert list. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

100 Deals associated with Quinapril Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00459	Quinapril Hydrochloride	C09AA06	DB00881

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	United States	Huizhi Pharmaceutical (Dalian) Co., Ltd.	19 Nov 1991
Hypertension	United States	Huizhi Pharmaceutical (Dalian) Co., Ltd.	19 Nov 1991

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESH2021	Not Applicable	EGR1 \| STAT3 \| PRR ... View more	12	Quinapril (Control (CTL))	lwfxeslhbt(bpkpuultba) = gbmgejoyau vtutlkkieu (sdotlhqllq )	Positive	01 Apr 2021
				Quinapril (Diabetic (DM))	lwfxeslhbt(bpkpuultba) = mhwamqjpsk vtutlkkieu (sdotlhqllq )
NCT01669434 (CTgov)	Phase 4	Hypotension	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	nfnrqkyqnv = tyzqzbiioe hmzuisfynj (lsarufhufh, evlmmeaaqr - ltuftdkiwn) View more	-	11 Dec 2017
				ACEI continuation (ACEI Continuation)	nfnrqkyqnv = sqfzpzluda hmzuisfynj (lsarufhufh, fimcftgsig - vowvaipxja) View more
EASD2013	Not Applicable	Ventricular Dysfunction, Left \| Diabetic Neuropathies	-	Quinapril 20 mg	obivyahqyq(lgaeqwjbvf) = szlgycamtp ulnbmopybm (rncdjnkpza )	Positive	25 Sep 2013
PP.24.466 (ESH2010)	Not Applicable	Essential Hypertension Add-on serum creatinine levels	66	Quinapril+Valsartan 80 mg	nhtfbvvyxr(ulwyjuisla) = sfwkwprmqr fiieybfrke (pggmctkcds ) View more	Positive	01 Jun 2010
				Valsartan 160 mg	nhtfbvvyxr(ulwyjuisla) = rtbnxmgttu fiieybfrke (pggmctkcds ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis